Reporter

Entrances to VUMC facilities to remain secured

VUMC is keeping most entrance points to its facilities secured in the same way they have been for the previous two-plus years.

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

Jacek Hawiger, MD, PhD, third from right, with study team members, from left, Katherine Gibson-Corley, DVM, PhD, Yan Liu, MD, Jozef Zienkiewicz, PhD, Huan Qiao, MD, PhD, and Ruth Ann Veach.

Hawiger still blazing a trail in inflammation research

Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

After two surgeries to remove tumors from her spine, patient Reagan Brown can walk freely again and has no limitations.

Spinal surgeries help restore young patient’s mobility

The clinical trial group includes, from left, Gordon Bernard, MD, Katherine Cahill, MD, Kevin Niswender, MD, PhD, Pingsheng Wu, PhD, and R. Stokes Peebles, MD.

Clinical trial at VUMC tests novel treatment for asthma

VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.

Study explores CVD risk for people with HIV

A Vanderbilt study found that among people with HIV infection, three types of CD4+ T helper cells are associated with incident cardiovascular disease (CVD) that are not explained by CVD risk.

1 62 63 64 65 66 725